A pharmaceutical company has repackaged a previously developed drug that addresses the symptoms of a scientifically questionable disorder affecting approximately 5 percent of women. Although few women are affected by the “disorder,” the company’s advertising strategy is comprehensive, including dozens of television, radio, and magazine ads. As a result, millions of women with symptoms similar to those of the disorder have sought prescriptions for the company’s drug. In turn, the company has made billions of dollars. What, if any, are the ethical implications of advertising a remedy to a mass audience when the affected group is small? Is the company misrepresenting its drug by conducting a “media blitz”? Why or why not?

AppendixLO1